Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Open Access Guideline
Open Access Guideline
Postgraduate Thesis Guideline
Postgraduate Thesis Guideline
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
Recent Developments in Glioblastoma-On-A-Chip for Advanced Drug Screening Applications
Date
2024-01-01
Author
Maity, Surjendu
Bhuyan, Tamanna
Jewell, Christopher
Kawakita, Satoru
Sharma, Saurabh
Nguyen, Huu Tuan
Hassani Najafabadi, Alireza
Ermiş Şen, Menekşe
Falcone, Natashya
Chen, Junjie
Mandal, Kalpana
Khorsandi, Danial
Yilgor, Can
Choroomi, Auveen
Torres, Emily
Mecwan, Marvin
John, Johnson V.
Akbari, Mohsen
Wang, Zhaohui
Moniz-Garcia, Diogo
Quiñones-Hinojosa, Alfredo
Jucaud, Vadim
Dokmeci, Mehmet Remzi
Khademhosseini, Ali
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
0
views
0
downloads
Cite This
Glioblastoma (GBM) is an aggressive form of cancer, comprising ≈80% of malignant brain tumors. However, there are no effective treatments for GBM due to its heterogeneity and the presence of the blood-brain barrier (BBB), which restricts the delivery of therapeutics to the brain. Despite in vitro models contributing to the understanding of GBM, conventional 2D models oversimplify the complex tumor microenvironment. Organ-on-a-chip (OoC) models have emerged as promising platforms that recapitulate human tissue physiology, enabling disease modeling, drug screening, and personalized medicine. There is a sudden increase in GBM-on-a-chip models that can significantly advance the knowledge of GBM etiology and revolutionize drug development by reducing animal testing and enhancing translation to the clinic. In this review, an overview of GBM-on-a-chip models and their applications is reported for drug screening and discussed current challenges and potential future directions for GBM-on-a-chip models.
Subject Keywords
disease modeling
,
drug screening
,
GBM
,
GBM-on-a-chip
,
tumor microenvironment
URI
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85208934284&origin=inward
https://hdl.handle.net/11511/112765
Journal
Small
DOI
https://doi.org/10.1002/smll.202405511
Collections
Biomaterials and Tissue Engineering Application and Research Center (BİOMATEN), Article
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
S. Maity et al., “Recent Developments in Glioblastoma-On-A-Chip for Advanced Drug Screening Applications,”
Small
, pp. 0–0, 2024, Accessed: 00, 2024. [Online]. Available: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85208934284&origin=inward.